Clene Announces $4M Registered Direct Offering; Funding Expected Through Q1 2027

Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional

Colgate-Palmolive (CL) is reportedly exploring the sale of non-core personal care brands, valued at over $1 billion, with Goldman Sachs' advisory. The move aims to reallocate capital toward higher-growth segments. CL shares are down 12% year-to-date, trading below major moving averages, but offer a 2.44% dividend yield. Institutional investors remain bullish, and the consensus rating is 'Moderate Buy' with a mean price target of $160.

Rivian (RIVN) has secured investments from Volkswagen (VWAGY) and Uber (UBER), with VWAGY becoming its largest shareholder. The company began R2 deliveries in June, targeting the large midsize SUV segment. Rivian has turned gross profit positive but withdrew its 2027 EBITDA guidance. It trades at a forward P/S multiple of 2.35x, with some analysts finding the valuation unattractive.

Smith & Nephew (LSE:SN, NYSE:SNN) priced a cash tender offer for up to $250M of its 2.032% Senior Notes due 2030. The offer expires today, with a settlement date expected on September 18, 2026. The tender offer consideration is $878.90 per $1,000 principal amount. The company may prorate the offer if oversubscribed.

Morgan Stanley plans to convert Eaton Vance state-specific municipal bond strategies into ETFs, offering lower costs and intraday trading. Analyst Eric Balchunas notes success depends on fees matching or undercutting institutional mutual fund levels. The fee structure will be key for investor interest.